Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same

Abstract

The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided

1 . A method of treating a gastric acid-related disease or disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising omeprazole in an amount of about 60 mg to about 140 mg, lansoprazole in an amount of amount of about 60 mg to about 140 mg, and at least one buffering agent in an amount of about 100 mg to about 4000 mg. 
     
     
         2 . The method of  claim 1 , wherein the at least one buffering agent is selected from the group consisting of: sodium bicarbonate, calcium carbonate, calcium formate, magnesium hydroxide, aluminum, aluminum hydroxide/magnesium hydroxide co-precipitate, aluminum hydroxide/sodium bicarbonate co-precipitate, calcium acetate, calcium bicarbonate, calcium borate, calcium bicarbonate, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium hydroxide, calcium lactate, calcium phthalate, calcium phosphates, calcium succinate, calcium tartrate, calcium propionate, dibasic sodium phosphate, dipotassium hydrogen phosphate, dipotassium phosphate, disodium hydrogen phosphate, disodium succinate, dry aluminum hydroxide gel, L-arginine, magnesium acetate, magnesium aluminate, magnesium borate, magnesium bicarbonate, magnesium carbonate, magnesium citrate, magnesium gluconate, magnesium lactate, magnesium metasilicate aluminate, magnesium oxide, magnesium phthalate, magnesium phosphate, magnesium silicate, magnesium succinate, magnesium tartrate, potassium acetate, potassium carbonate, potassium bicarbonate, potassium borate, potassium citrate, potassium metaphosphate, potassium phthalate, potassium phosphate, potassium polyphosphate, potassium pyrophosphate, potassium succinate, potassium tartrate, sodium acetate, sodium borate, sodium carbonate, sodium citrate, sodium gluconate, sodium hydrogen phosphate, sodium hydroxide, sodium lactate, sodium phthalate, sodium phosphate, sodium polyphosphate, sodium pyrophosphate, sodium sesquicarbonate, sodium succinate, sodium tartrate, sodium tripolyphosphate, synthetic hydrotalcite, tetrapotassium pyrophosphate, tetrasodium pyrophosphate, tripotassium phosphate, trisodium phosphate, trometamol, and mixtures of the foregoing. 
     
     
         3 . The method of  claim 1 , wherein the at least one buffering agent comprises calcium carbonate and is present in an amount of about 400 mg to about 2500 mg. 
     
     
         4 . The method of  claim 1 , wherein the at least one buffering agent comprises calcium formate and is present in an amount of about 400 mg to about 2500 mg. 
     
     
         5 . The method of  claim 1 , wherein the at least one buffering agent comprises calcium carbonate and calcium foimate. 
     
     
         6 . The method of  claim 5 , wherein the calcium carbonate is present in an amount of about 300 mg to about 3000 mg and the calcium formate is present in an amount of about 100 mg to about 4000 mg. 
     
     
         7 . The method of  claim 1 , further comprising one or more pharmaceutically acceptable excipients. 
     
     
         8 . The method of  claim 7 , wherein the one or more pharmaceutically acceptable excipient is selected from the group consisting of: diluents, disintegrants, binding agents, adhesives, wetting agents, lubricants, glidants, surface modifying agents, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition. 
     
     
         9 . The method of  claim 8 , wherein the disintegrant is selected from the group consisting of:
 croscarmellose sodium and sodium carboxymethylcellulose.   
     
     
         10 . The method of  claim 8 , wherein the lubricant is magnesium stearate. 
     
     
         11 . The method of  claim 1  wherein the composition is present in one or more discrete dosage units. 
     
     
         12 . The method of  claim 11 , wherein the one or more discrete dosage units are selected from tablets, caplets, capsules, powder, lozenges, sachets, cachets, troches, pellets, granules and mixtures thereof 
     
     
         12 . The method of  claim 1  wherein the lansoprazole is present in an amount of about 50 mg to about 150 mg. 
     
     
         13 . The method of  claim 1  wherein the omeprazole is present in an amount of about 70 mg to about 100 mg and the lansoprazole is present in an amount of about 70 mg to about 100 mg. 
     
     
         14 . The method of  claim 1  wherein the buffering agent comprises sodium bicarbonate. 
     
     
         15 . The method of  claim 1  wherein the buffering agent comprises sodium bicarbonate, calcium carbonate and/or calcium formate. 
     
     
         16 . The method of  claim 11  wherein the composition is administered to the subject daily for a period effective to treat said disease or disorder. 
     
     
         17 . The method of  claim 1 , wherein the gastric acid-related disease or disorder is selected from the group consisting of severe erosive esophagitis (Los Angeles classification grade C & D), Barrett's esophagus, reflux-related esophageal metaplasia with low or high grade dysplasia, reflux-related adenocarcinoma of the esophagus, acid-related adenocarcinoma of the stomach, duodenal ulcer, gastric ulcer, gastric and duodenal erosions and ulcerations, acid dyspepsia, gastroesophageal reflux disease (GERD), poorly responsive symptomatic GERD, acid reflux, esophageal ulcers and erosions, precancerous and canercous lesions of the esophagus induced by acid exposure, radiation- or chemotherapy-induced esophagitis, acid hypersecretory conditions, gastrointestinal pathological hypersecretory conditions, Zollinger Ellison Syndrome, non-ulcer dyspepsia, short-term eradication of  Helicobacter pylori  ( H. pylori ), extraesophageal or atypical manifestations of gastroesophageal reflux disease, nocturnal acid breakthrough (NAB), sleep apnea, sleep disturbance, gastrointestinal bleeding, rebleeding after gastrointestinal bleeding, stress ulcer prevention, stress-related bleeding, seizure or apparent seizure activity, Sandifer's syndrome, failure to thrive, anorexia, anorexia nervosa, weight loss, apnea, and bradycardia. 
     
     
         18 . The method of  claim 1 , wherein the subject has gastroparesis. 
     
     
         19 . The method of  claim 1 , wherein the subject does not have gastropareises. 
     
     
         20 . The method of  claim 17 , wherein the extraesophageal or atypical manifestations of gastroesophageal reflux disease are selected from the group consisting of eye pain, asthma, bronchitis, pneumonia, chest pain, cough, recurrent laryngitis, globus pharyngeus, sinusitis, otalgia, otitis media, eustachian tube dysfunction, voice change, globus sensation, throat clearing, halitosis, sore throat, and aphthous ulcers. 
     
     
         21 . The method of  claim 1 , wherein the pharmaceutical composition is administered prior to endoscopic evaluation of upper GI bleeding.